Search results for "Cost-benefit analysi"

showing 10 items of 148 documents

Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease : results from the EUROASPIRE IV …

2018

Background: This study aims to assess the cost-effectiveness of optimized guideline adherence in patients with a history of coronary heart disease. Methods: An individual-based decision tree model was developed using the SMART risk score tool which estimates the 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease (CVD). Analyses were based on the EUROASPIRE IV survey. Outcomes were expressed as an incremental cost-effectiveness ratio (ICER). Results: Data from 4663 patients from 13 European countries were included in the analyses. The mean estimated 10-year risk for a recurrent vascular event decreased from 20.13% to 18.61% after optimized guideline a…

MaleCardiac & Cardiovascular SystemsCost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisCoronary DiseaseDisease030204 cardiovascular system & hematology0302 clinical medicineOlder patientsMedicine030212 general & internal medicineguidelinesEUROASPIRE1102 Cardiorespiratory Medicine and Haematologyhealth care economics and organizationsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Framingham Risk ScoreSecondary preventionASSOCIATIONMiddle AgedhumanitiesCoronary heart diseaseEuropeDENSITY-LIPOPROTEIN CHOLESTEROLPractice Guidelines as TopicTRIALFemaleGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary prevention ; guidelines ; cost-effectiveness ; coronary heart disease ; EUROASPIREsecondary preventionmedicine.drugINTERVENTIONSmedicine.medical_specialtyEZETIMIBEGuidelinesEVENTS03 medical and health sciencesEzetimibeInternal medicineHumansIn patientcoronary heart diseaseBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.cost-effectivenessMETAANALYSISAgedScience & Technologybusiness.industryDecision TreesSMOKING-CESSATIONCoronary heart diseaseTHRESHOLDSCardiovascular System & HematologyCardiovascular System & CardiologySmoking cessationCost-effectivenessbusinessSTATIN TREATMENT
researchProduct

Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.

2008

The aim of this study was to compare the analgesic and adverse effects, doses, as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in patients treated with oral sustained-release morphine, transdermal fentanyl, and oral methadone.One hundred and eight cancer patients, no longer responsive to opioids for moderate pain, were selected to randomly receive initial daily doses of 60 mg of oral sustained-release morphine, 15 mg of oral methadone, or 0.6 mg (25 microg/h) of transdermal fentanyl. Oral morphine was used as breakthrough pain medication during opioid titration. Opioid doses, pain intensity, adverse effects, symptomatic drugs, were recorded at week interva…

MaleCost-Benefit AnalysisAdministration OralFentanylNeoplasmscancer pain opioidsProspective StudiesCancer painTransdermalIntractableAnalgesicsMorphineMiddle AgedPain IntractableAnalgesics OpioidFentanylNeuropsychology and Physiological PsychologyTreatment OutcomeNeurologyPatient SatisfactionAnesthesiaAdministrationFemaleDrugmedicine.drugOralAdultAdolescentAnalgesicPainOpioidAdministration CutaneousDrug Administration ScheduleDose-Response RelationshipmedicineHumansAdverse effectAgedDose-Response Relationship Drugbusiness.industryCostsCutaneousAnesthesiology and Pain MedicineOpioidCancer pain; Costs; Fentanyl; Methadone; Morphine; Administration Cutaneous; Administration Oral; Adolescent; Adult; Aged; Analgesia; Analgesics Opioid; Cost-Benefit Analysis; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Fentanyl; Humans; Male; Methadone; Middle Aged; Morphine; Neoplasms; Pain Intractable; Patient Satisfaction; Prospective Studies; Quality of Life; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neuropsychology and Physiological PsychologyMorphineQuality of LifeAnalgesiaCancer painbusinessMethadoneMethadoneEuropean journal of pain (London, England)
researchProduct

Assessment of the mutagenic potency of sewage sludges contaminated with polycyclic aromatic hydrocarbons by an Ames sludges for fluctuation assay

2003

9 pages, 1 figure, 6 tables.-- PMID: 14587895 [PubMed].

MaleCost-Benefit AnalysisHealth Toxicology and MutagenesisSewageFractionationGene mutationSensitivity and SpecificityWaste Disposal FluidAmes testReference ValuesMutagenicityAnimalsEnvironmental ChemistryCitiesRats WistarSewage sludgeChromatographySewageMutagenicity Testsbusiness.industryChemistryReproducibility of ResultsAmes fluctuation assayPolycyclic aromatic hydrocarbonsRatsEnvironmental chemistryGas chromatography-mass spectrometrySewage treatmentGas chromatography–mass spectrometrybusinessSludgeDNA DamageWaste disposal
researchProduct

Predation as a landscape effect: the trading off by prey species between predation risks and protection benefits.

2007

1. Predators impose costs on their prey but may also provide benefits such as protection against other (e.g. nest) predators. The optimal breeding location in relation to the distance from a nesting raptor varies so as to minimize the sum of costs of adult and nest predation. We provide a conceptual model to account for variation in the relative predation risks and derive qualitative predictions for how different prey species should respond to the distance from goshawk Accipiter gentilis nests. 2. We test the model predictions using a comprehensive collection of data from northern Finland and central Norway. First, we carried out a series of experiments with artificial bird nests to test if…

MaleCost-Benefit AnalysisOvipositionForagingPopulation DynamicsRisk AssessmentPredationNesting BehaviorBirdsSongbirdsNestSpecies SpecificityAbundance (ecology)AnimalsNest boxEcology Evolution Behavior and SystematicsPopulation DensitybiologyRaptorsEcologyReproductionAccipiterBird nestbiology.organism_classificationHabitatPredatory BehaviorAnimal Science and ZoologyFemaleThe Journal of animal ecology
researchProduct

Anticancer oral therapy: Emerging related issues

2010

The use of oral anticancer drugs has shown a steady increase. Most patients prefer anticancer oral therapy to intravenous treatment primarily for the convenience of a home-based therapy, although they require that the efficacy of oral therapy must be equivalent and toxicity not superior than those expected with the intravenous treatment. A better patient compliance, drug tolerability, convenience and possible better efficacy for oral therapy as compared to intravenous emerge as the major reasons to use oral anticancer agents among oncologists. Inter- and intra-individual pharmacokinetic variations in the bioavailability of oral anticancer drugs may be more relevant than for intravenous agen…

MaleCost-Benefit AnalysisPsychological interventionAdministration OralPharmacologyAntineoplastic AgentPharmacogenomicNeoplasmsMedicineDrug InteractionsInfusions IntravenouInfusions IntravenousCancermedia_commonOraltherapyGeneral MedicineTreatment OutcomeDrug InteractionOncologyTolerabilityPatient SatisfactionFemaleComplianceDrug-drug interactionHumanQuality of lifeDrugmedicine.medical_specialtyCostmedia_common.quotation_subjectPharmacokineticAntineoplastic AgentsDrug Administration ScheduleFollow-Up StudiePersistenceQuality of life (healthcare)Patient satisfactionPharmacokineticsHumansRadiology Nuclear Medicine and imagingCost-Benefit AnalysiAdverse effectIntensive care medicineDose-Response Relationship Drugbusiness.industryAdherencePharmacogenomicsNeoplasmPatient CompliancebusinessFollow-Up StudiesForecastingCancer Treatment Reviews
researchProduct

Refined Analysis of the Critical Age Ranges of Childhood Overweight: Implications for Primary Prevention

2012

Prevention-interventions would certainly benefit from a precise knowledge of the age range when the most pronounced increases in prevalence of overweight and obesity occur in the general population. Data of 15,662 subjects aged 2-18 years were obtained from a national representative health survey (German Health Interview and Examination Survey for Children and Adolescents (KiGGS)) conducted in Germany. Weight, height, and BMI z-scores were calculated relative to the UK 1990 reference, and prevalence of overweight and obesity was defined according to the IOTF (International Obesity Task Force) age- and sex-specific cut-offs. Univariate ANOVAs for overweight, obesity, weight, height, and BMI …

MaleGerontologyAdolescentCross-sectional studyCost-Benefit AnalysisEndocrinology Diabetes and MetabolismPopulationMedicine (miscellaneous)OverweightBody Mass Indexsymbols.namesakeSex FactorsEndocrinologyReference ValuesGermanyPrevalencemedicineHumansObesityChildeducationAnalysis of Varianceeducation.field_of_studyNutrition and Dieteticsbusiness.industryBody WeightAge FactorsInfant NewbornInfantmedicine.diseaseObesityPrimary PreventionCross-Sectional StudiesBonferroni correctionChild PreschoolsymbolsFemaleAnalysis of variancemedicine.symptombusinessPsychosocialBody mass indexDemographyObesity
researchProduct

Short-term cost-effectiveness of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: Results from the SOPHO-NET trial

2015

Abstract Background To investigate the short-term cost-effectiveness of cognitive-behavioral therapy (CBT) and psychodynamic therapy (PDT) compared to waiting list (WL). Methods The analysis was conducted alongside the SOPHO-NET multi-center efficacy trial. Patients were randomly assigned to CBT ( n =209), PDT ( n =207), or WL ( n =79). Resource use was assessed prior and during treatment to determine direct and absenteeism costs. Unadjusted incremental cost-effectiveness ratios (ICERs) were calculated based on remission and response rates. To visualize statistical uncertainty, cost-effectiveness acceptability curves (CEACs) were constructed based on adjusted net-benefit regression. Differe…

MaleMental Health Servicesmedicine.medical_specialtyTime FactorsWaiting ListsCost effectivenessCost-Benefit Analysismedicine.medical_treatmentPsychological interventionGroup psychotherapyIndirect costsWillingness to paymedicineHumansPsychiatryhealth care economics and organizationsCognitive Behavioral TherapyMiddle Aged3. Good healthCognitive behavioral therapyPsychiatry and Mental healthClinical PsychologyTreatment OutcomePhobic DisordersEconomic evaluationAbsenteeismPhysical therapyFemalePsychologyJournal of Affective Disorders
researchProduct

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2014

Abstract Background We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy. Methods Cost-effectiveness analysis performed according to data from the available published literature. The target population was composed of untreated Caucasian patients, aged 50 years, with genotype 1 chronic hepatitis C, and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian Nati…

MaleNational Health ProgramsCost effectivenessCost-Benefit AnalysisHepacivirusNational Health ProgramHepacivirusPharmacologyPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundQuality-Adjusted Life YearMedicineSettore SECS-S/05 - Statistica SocialeMultivariate AnalysiBoceprevirSettore MED/12 - GastroenterologiabiologyMedicine (all)GastroenterologyMiddle AgedRecombinant ProteinMarkov ChainsRecombinant ProteinsModels EconomicTreatment OutcomeItalyDrug Therapy CombinationFemaleQuality-Adjusted Life YearsSettore SECS-S/01 - StatisticaViral loadHumanmedicine.medical_specialtyGenotypeProlineAlpha interferonInterferon alpha-2Antiviral AgentsInternal medicineBoceprevirRibavirinHumansCost-Benefit AnalysiAntiviral AgentHepaciviruPeg-interferonHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C ChronicMarkov Chainbiology.organism_classificationQuality-adjusted life yearchemistryCost-effectiveneMultivariate AnalysisQuality of LifeCost-effectivenessbusiness
researchProduct

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

2013

The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for …

MaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCost effectivenessCost-Benefit AnalysisSettore MED/12 - GASTROENTEROLOGIAAged; Antineoplastic Agents; Carcinoma Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life YearsAntineoplastic AgentsKaplan-Meier EstimateDrug CostsInternal medicinemedicineHumansProspective StudiesProspective cohort studyneoplasmsSurvival rateAgedHepatologyPerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsCarcinomaHepatocellular carcinoma sorafenib ICER cost-effectivenessHepatocellularSorafenibmedicine.diseaseMarkov Chainsdigestive system diseasesSurgeryQuality-adjusted life yearHepatocellular carcinomaMultivariate AnalysisQuality-Adjusted Life YearsbusinessLiver cancermedicine.drugHepatology
researchProduct

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-s…

2010

Abstract Background The objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with predominantly non-squamous histology in the Spanish healthcare setting. Methods A Markov model was designed consisting of stable, responsive, progressive disease and death states. Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for non-squamous patients treated with pemetrexed compared …

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyGuanineLung NeoplasmsCost-Benefit AnalysisPopulationDocetaxelPemetrexedlcsh:RC254-282Disease-Free SurvivalGlutamatesSurgical oncologyCarcinoma Non-Small-Cell LungCell Line TumorInternal medicineGeneticsCarcinomamedicineHumanseducationLung cancerneoplasmseducation.field_of_studybusiness.industryCarcinomaHistologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMarkov Chainsrespiratory tract diseasesQuality-adjusted life yearTreatment OutcomePemetrexedOncologyDocetaxelSpainDisease ProgressionQuality of LifeFemaleTaxoidsQuality-Adjusted Life YearsbusinessResearch Articlemedicine.drugBMC Cancer
researchProduct